SCHEMBL1496282

SCHEMBL1496282

O=C(Nc1ccc(Cl)cc1)c1ccccc1SCc1ccnc2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.64
FLT1 P17948 2/20 0.57
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
OPRL1 P41146 1/20 0.51
IDO1 P14902 2/20 0.48
NPC1 O15118 1/20 0.45
TSHR P16473 1/20 0.45
LMNA P02545 1/20 0.44
ACLY P53396 1/20 0.44
POLB P06746 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
DNMT1 P26358 1/20 0.44
DNMT3L Q9UJW3 1/20 0.44
DNMT3A Q9Y6K1 1/20 0.44
PABPC1 P11940 1/20 0.43
EIF4H Q15056 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1496366 0.87 KDR (0.66) KDRFLT1MEN1KMT2AOPRL1
SCHEMBL1496283 0.87 ACLY (0.50) KDRFLT1OPRL1NPC1LMNA
SCHEMBL1496358 0.86 KDR (0.59) KDRFLT1MEN1KMT2ALMNA
SCHEMBL1496374 0.85 KDR (0.59) KDRFLT1
SCHEMBL1496259 0.85 KDR (0.58) KDRMEN1KMT2AOPRL1NPC1
SCHEMBL1496331 0.84 PKM (0.56) KDRMEN1KMT2ALMNAPOLB
SCHEMBL1496324 0.83 KDR (0.63) KDRFLT1KMT2AOPRL1IDO1
SCHEMBL4977752 0.79 KDR (0.55) KDRFLT1MEN1KMT2AOPRL1
SCHEMBL1347578 0.79 KDR (0.55) KDRFLT1MEN1KMT2AOPRL1
SCHEMBL1496378 0.79 SMN1; SMN2 (0.44) KDRFLT1KMT2ALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897774-B2 Cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-01 US claimed
EP-1854787-B1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO LTD (JP) 2010-09-01 EP claimed
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US claimed
EP-1854787-A1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-11-14 EP claimed
US-7897774-B2 Cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-01 US disclosed
EP-1854787-B1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO LTD (JP) 2010-09-01 EP disclosed
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US disclosed
EP-1854787-A1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SQOR, QSOX1, SQLE KDR 3463/4885FLT1 2060/4885MEN1 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.